Core Viewpoint - The increasing prevalence of metabolic dysfunction-related fatty liver disease (MASH) necessitates the development of new therapeutic strategies, as current treatment options are limited and the patient population is growing rapidly [2][5]. Group 1: MASH Overview - Approximately 100 million people globally are currently affected by MASH, with projections indicating this number could rise to 357 million by 2030 [2]. - MASH is a critical factor in the progression of liver cirrhosis and hepatocellular carcinoma, and it is a leading cause of liver transplants [2]. Group 2: Research Findings - A new strategy for large-scale acquisition of artificial cell-derived vesicles (ACDV) has been proposed, which allows for the safe and stable oral delivery of RNA drugs targeting the liver [3]. - The study demonstrated that LIMA1 siRNA (siLIMA1) delivered via the modified ACDV effectively inhibited LIMA1 protein expression in the liver, thereby preventing MASH progression and improving liver function [3][11]. Group 3: Mechanism of Action - The development of drugs targeting metabolism, inflammation, and fibrosis is crucial, as excessive accumulation of fats and other metabolic substrates leads to chronic inflammation and liver cell damage [5]. - LIMA1 gene silencing is identified as a promising therapeutic approach for MASH, given its upregulation in lipotoxic liver cells and its role in liver fibrosis associated with metabolic dysfunction [5][6]. Group 4: Delivery System - The study highlights the potential of red blood cell (RBC)-derived extracellular vesicles (RBC-EV) as a non-immunogenic delivery option for RNA drugs, although challenges remain in large-scale production and half-life limitations [7]. - A feasible strategy involves generating ACDV by squeezing red blood cells, which can then be modified with DSPE-PEG and cholic acid to enhance structural integrity and liver-targeting capabilities [8][9]. Group 5: Conclusion - The research indicates that ACDV can be easily obtained and modified to achieve oral liver-targeting capabilities, with the delivery of LIMA1-siRNA showing significant therapeutic effects against MASH [13].

Core Viewpoint - The 31st China Lanzhou Investment and Trade Fair is being held in Lanzhou, Gansu Province, focusing on the theme of "Sharing Opportunities, Seeking Development, and Creating Prosperity" [1] Group 1: Event Overview - The fair features participation from 24 diplomatic missions and business associations, along with exhibitors from 18 provinces (regions, municipalities) and the Hong Kong Special Administrative Region [1] - Nearly 2,000 enterprises are participating, showcasing products across nearly 40 categories, including equipment manufacturing, petrochemicals, biomedicine, new materials, new energy, aerospace, modern agriculture, data information, low-altitude economy, artificial intelligence, green minerals, cultural tourism and health, specialty agricultural products, and daily consumer goods [1]

从生物医药到高端制造，广西科技成果正以多元应用书写发展新篇章。7月4日，2025年广西科学技 术奖励大会在南宁召开，会议表彰了2024年度广西科学技术奖获奖组织、人员。2024年度广西科学技术 奖获奖成果160项，涵盖基础研究、技术突破、产业创新等多个领域，展现了广西在科技创新领域的蓬 勃发展态势。 从乡村走出的科研赤子：赵永祥的创新之路 广西医科大学赵永祥教授获得2024年度广西最高科学技术奖。其在肿瘤生物靶向诊治领域的突破性 成果引发广泛关注。 在大会现场，赵永祥教授作为获奖代表发言，讲述了他从农村学子到科研领军者的奋斗历程。2009 年，他毅然放弃国家重点实验室的优越条件，奔赴广西投身科研事业。面对旁人的不解，他坚定表 示："科学无疆界，祖国需要的地方，就是我心之所向。" 青年科技工作者是科研队伍的新生力量，更是企业创新突破的生力军与引擎。广西柳工机械股份有 限公司王松林、柳州欧维姆机械股份有限公司邹易清获得2024年度青年科技杰出贡献奖。王松林长期从 事工程机械传动系统基础研究及重大技术攻关，2021—2023年主持研发的新产品累计销售收入2亿元。 邹易清近十年坚持探索预应力技术国际前沿，创新研发预应 ...

Group 1 - The Ministry of Commerce announced the final ruling on anti-dumping investigations related to imported brandy from the EU, accepting price commitment applications from 34 companies, which will not be subject to anti-dumping duties if conditions are met [3] Group 2 - Multiple airlines have announced an increase in domestic fuel surcharges effective from July 5, with charges set at 10 yuan for flights under 800 kilometers and 20 yuan for flights over 800 kilometers [4] Group 3 - Guizhou Renhuai has launched a special governance action for the liquor market, emphasizing quality and integrity in the liquor industry amid a period of deep adjustment [4] Group 4 - Microsoft plans to lay off approximately 9,000 employees, marking its largest round of layoffs since cutting 10,000 jobs earlier in 2023 [11] Group 5 - Xiaomi's Yu7 vehicle will begin deliveries on July 6 across 58 cities, indicating a significant step in its automotive business development [12] Group 6 - Meituan's instant retail orders exceeded 120 million on July 5, triggering server protection due to the peak order volume [16][17] Group 7 - Shunde Rural Commercial Bank has withdrawn its IPO application after six years of preparation, impacting the A-share banking IPO landscape [18] Group 8 - Hengrun Dashing has submitted its application for the Sci-Tech Innovation Board using the fifth set of listing standards, which may influence the layout of the biopharmaceutical sector on the board [19] Group 9 - Shanghai Lego Land officially opened on July 5, significantly increasing search volume and ticket bookings, indicating a positive impact on the tourism industry [20]

Group 1 - The U.S. government is set to implement new unilateral tariff rates starting August 1, with rates potentially ranging from 10% to 70% [2] - The EU's final ruling on anti-dumping measures for imported brandy allows 34 companies to avoid anti-dumping duties if they meet price commitments [2] Group 2 - The Chinese government emphasizes accelerating technological innovation in agriculture and healthcare to enhance industry quality and economic development [3] - France expresses willingness to deepen mutually beneficial cooperation with China, particularly in investment and addressing trade differences [3] Group 3 - The expansion of China's visa-free travel policy to 47 countries has boosted inbound tourism and shopping, with new tax refund policies implemented in Dalian and Hubei [4] - The CEO of a major asset management firm anticipates further development of the QDLP policy, highlighting the attractiveness of Chinese companies for long-term investment [4] Group 4 - The Shanghai Stock Exchange is enhancing communication with private equity firms to support technology innovation and market opportunities [5] - A biopharmaceutical company has submitted an application to list on the STAR Market under a new standard that accommodates unprofitable companies [5] - The withdrawal of IPO applications by small banks indicates a slowdown in their listing processes, with only five banks remaining in the queue [5] Group 5 - Hong Kong's stock market has outperformed major indices, with funds shifting towards less crowded sectors as valuations remain low [6] - New insurance investment reforms have seen over 200 billion yuan allocated to long-term investments [6] - A total of 44 brokerage firms have recommended 279 A-shares as "golden stocks" for July, with a significant focus on the electronics and machinery sectors [6] Group 6 - The second half of the year sees a notable increase in the trading volume of used cars in China, with a slight year-on-year growth [8] - The civil aviation market is experiencing a surge in ticket bookings as the summer travel season begins [9] Group 7 - The establishment of the Yangtze River M&A Alliance aims to support the transformation of traditional industries and the development of emerging sectors in Hubei [11] - A new investment fund focused on humanoid robots and AI has been set up in Hubei, with a total scale of 10 billion yuan [11] Group 8 - The Bank of England's governor emphasizes the need for public trust in currencies as stablecoins emerge as a new payment method [12] - Concerns arise over the potential impact of U.S. stablecoin legislation on global payment systems [12] Group 9 - Huawei's latest model, the Pangu Pro MoE, is developed on its Ascend hardware platform, adhering to open-source licensing [13] - Foxconn reports record revenue for June, indicating strong performance in the second quarter [13] Group 10 - The establishment of a new political party by Elon Musk reflects ongoing debates over U.S. tax and energy policies [14] - Japan is actively negotiating with the U.S. regarding tariff issues as new tariffs approach [14] Group 11 - The London Stock Exchange sees a significant drop in IPO fundraising, raising concerns about its attractiveness as a global capital center [15] - Japan experiences a surge in individual shareholders, driven by tax incentives and investment trends [15] Group 12 - The OPEC+ agreement to increase oil production in August indicates a response to market expectations [18] - The recent rise in metal prices, particularly copper, is attributed to supply chain adjustments ahead of tariff deadlines [18]

Core Viewpoint - The article discusses the recent submission of listing materials by Hengrun Dashing, a biopharmaceutical company, under the fifth set of listing standards on the Sci-Tech Innovation Board, highlighting the trend of allowing unprofitable companies to list, which supports the development of high-quality technology enterprises [2][3][9]. Group 1: Company Overview - Hengrun Dashing is a biopharmaceutical company focused on innovative immune cell therapy products, particularly in the treatment of malignant blood diseases and solid tumors [6]. - The company has a pipeline of 11 research projects, including 10 major products utilizing technologies such as CAR-T and CAR-NK [6]. - As of the date of the prospectus, all products are still in the research and development phase, with no commercial sales or profitability expected in the near future [5][6]. Group 2: Financial Performance - The company has reported significant projected losses for the upcoming years, with net profits expected to be -273.71 million yuan, -283.65 million yuan, and -187.76 million yuan for 2022, 2023, and 2024 respectively [5]. - Cumulative undistributed profits amount to -904.15 million yuan as of the report date [5]. Group 3: Listing Standards and Market Context - The fifth set of listing standards on the Sci-Tech Innovation Board is designed for companies with complex product technologies, high capital requirements, and long research cycles, particularly in the biopharmaceutical sector [9]. - Since the establishment of the Sci-Tech Innovation Board in 2019, 54 unprofitable companies have successfully listed, with 22 of them achieving profitability post-listing [9]. - The resumption of the fifth set of listing standards is seen as a positive move to enhance the inclusivity and adaptability of the regulatory framework for high-quality unprofitable technology enterprises [3][9].

Core Insights - Wuhan has achieved a significant breakthrough with the world's first public demonstration of a one-kilometer high-speed magnetic levitation test line, reaching speeds of 650 kilometers per hour, which supports aerospace launches and low-altitude economic development [1] - The city is leveraging its "Five Valleys" innovation framework—Optics Valley, Automotive Valley, Aerospace Valley, Cybersecurity Valley, and Pharmaceutical Valley—to enhance its core competitiveness and drive economic growth [1][2] Group 1: Five Valleys Overview - Optics Valley is projected to grow from a scale of approximately 459.7 billion yuan in 2020 to 756.6 billion yuan by 2024, marking a 64.5% increase over four years [2] - Automotive Valley has transitioned from solely gasoline vehicles to a mix of gasoline and electric vehicles, with the share of new energy vehicles rising from 7% in 2021 to 41% last year [2] - Aerospace Valley has established a national aerospace industry base, completing over 50 satellite assembly and integration tests since its opening in 2021 [2] - Cybersecurity Valley has developed a network security talent pool, training over 3,000 professionals since the establishment of cybersecurity programs at local universities [2] - Pharmaceutical Valley has advanced from no innovative drugs in 2020 to four innovative drugs entering the market process by 2024, with 400 more in development [2] Group 2: Synergistic Development - The "Five Valleys" strategy promotes collaborative development among emerging industries, traditional industries, and future industries, enhancing Wuhan's industrial output and GDP growth potential [3] - The integration of technologies across the valleys, such as the collaboration between Cybersecurity Valley and Automotive Valley for vehicle network security, exemplifies the synergistic effects of the innovation ecosystem [3][4] - The interconnectedness of the valleys is fostering a complete industrial chain that includes research, manufacturing, services, and consumption [4] Group 3: Strategic Importance - Wuhan is positioning itself as a high-energy city with a modern industrial system, leveraging its advantages in digital economy infrastructure, automotive industry standards, aerospace economic positioning, data sovereignty, and life sciences [5] - The city is recognized as a leader in global technology innovation, with its innovation clusters ranking prominently among the world's top 100 [6] - The "Five Valleys" framework is seen as a critical driver for Wuhan's role in national strategic technology initiatives and its contribution to high-quality economic development [5][6]

Group 1 - The current investment landscape requires attention to the resonance between policies and industries, with a focus on three short-term hotspots: the financial technology sector driven by the upcoming implementation of Hong Kong's Stablecoin Regulation on August 1, the benefits for leading companies from photovoltaic supply-side reforms, and opportunities arising from the intensive rollout of innovative drug policies [1][5] - The A-share market showed a notable divergence from the Hong Kong market, with the Shanghai Composite Index rising by 0.32% to 3472.32 points, while the Shenzhen Component and ChiNext Index fell by 0.25% and 0.36% respectively, indicating a mixed performance across different sectors [2] - In the A-share market, the banking sector led with a 1.84% increase, while the innovation drug sector saw multiple stocks hitting the daily limit up, reflecting market recognition of financial stability and policy dividends [3][4] Group 2 - The photovoltaic sector in the Hong Kong market rebounded strongly due to expectations of supply-side reforms, with Xinyi Energy surging by 15%, while the biopharmaceutical sector also saw significant gains, such as Rongchang Bio rising over 15% due to supportive policies for innovative drugs [3][4] - The Ministry of Industry and Information Technology is focusing on addressing low-price competition in the photovoltaic industry, while the National Healthcare Security Administration has released measures to support the high-quality development of innovative drugs, providing substantial support in areas such as research data and insurance coverage [4] - The sales revenue of high-tech manufacturing industries increased by 12.1% year-on-year in the first five months, with intelligent equipment manufacturing growing by 19.4%, indicating strong momentum for industrial upgrades [4]

Group 1 - The core viewpoint of the article is that Weiming Pharmaceutical's core subsidiary has triggered a production halt, leading to a risk warning and a change in stock abbreviation to "ST Weiming" [2][6] - Weiming Pharmaceutical's subsidiary, Tianjin Weiming, is expected to be unable to resume normal operations within three months, significantly impacting the company's production and operations [5][10] - The stock will be suspended for one day on July 7 and will resume trading on July 8 with a new risk warning, limiting daily price fluctuations to 5% [2][5] Group 2 - Tianjin Weiming's production halt affects approximately 60% of Weiming Pharmaceutical's revenue, with an expected revenue of 217 million yuan in 2024 [4][5] - The company has faced ongoing internal control risks, including issues with disclosure of related party transactions and inaccurate earnings forecasts, leading to regulatory penalties [10][11] - Weiming Pharmaceutical has reported continuous losses over the past three years, with net profits of -14.68 million yuan, -332 million yuan, and -137 million yuan for 2022, 2023, and 2024 respectively [10][11] Group 3 - The company plans to cooperate with regulatory authorities to rectify deficiencies and aims to restore production as soon as possible [10] - Other subsidiaries of Weiming Pharmaceutical are currently operating normally, and the company intends to optimize management and reduce costs to maintain stable operations [10][11] - The stock price as of July 4 was 11.02 yuan per share, with a total market capitalization of 7.27 billion yuan [12]

编辑丨王多鱼 排版丨水成文 电压门控钠 （ Na v ） 通道通过介导膜去极化时钠离子 （ Na + ） 的快速内流来控制神经元和肌肉的膜兴奋性。这些功能由核 心的 Na v 结构驱动，该结构由一 个中央孔道结构域 （PD） 和四个环绕的电压感受结构域 （VSD） 组成。 在人类的九种 Na v 亚型 （Na v 1.1 - 1.9） 中，由 SCN8A 基因编码的 Na v 1.6 在中枢神经系统中广泛表达，尤其在轴突远端起始段的密度极高，其功能紊乱 与 癫痫 等神经疾病密切相关。然而，Na v 1.6 虽然功能强大，但靶向药物极少，开发其精准、特异性强的新型分子一直是神经药理领域的一大挑战。 2025 年 7 月 4 日 ， 深圳医学科学院 颜宁 / 黄健 团队在 Cell Research 期刊发表了题为： Phrixotoxin-3 binds to three distinct antagonistic sites on human Na v 1.6 的研究论文。 该研究首次揭示了 蜘蛛毒素 Phrixotoxin-3 （PaurTx3） 通过三位点协同调控人源电压门控钠通道 Na v 1.6 ，为 ...